Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib (Section 7.6) is an on-target, mechanism-based class effect.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib, a selective COX-2 inhibitor, was withdrawn from the market in 2004 following the VIGOR and APPROVe trials, which revealed a sustained excess of thrombotic cardiovascular events.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal efficacy and short-term human safety data had been reassuring; only long-term cardiovascular outcome trials surfaced the signal.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mechanism is generally ascribed to disruption of the prostacyclin–thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A2 production [77,78].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Items 401–500 of 1,003
Atzeni, F., Turiel, M., Caporali, R. F., Cavagna, L., TOMASONI, L., Sitia, S., & Sarzi‐Puttini, P. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.07.018 · Cited by 92
Hereditary Colorectal Cancer Syndromes: Familial Adenomatous Polyposis and Lynch Syndrome
Al-Sukhni, W., Aronson, M. D., & Gallinger, S. (2008) · Surgical Clinics of North America · doi:10.1016/j.suc.2008.04.012 · Cited by 101
The Safety and Efficacy of Celecoxib in Children With Familial Adenomatous Polyposis
Lynch, P. M., Ayers, G. D., Hawk, E., Richmond, E. S., Eagle, C. J., Woloj, M., Church, J. M., Hasson, H., Patterson, S. L., Half, E., et al. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.758 · Cited by 87
Greenspan, E. J., Madigan, J. P., Boardman, L. A., & Rosenberg, D. W. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0021 · Cited by 95
Wilcox, C. M., Allison, J. J., Benzuly, K. H., Borum, M. L., Cryer, B., Großer, T., Hunt, R. H., Ladabaum, U., Lanas, Á., Paulus, H. E., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.010 · Cited by 98
Role of Shear Stress in Endothelial Cell Morphology and Expression of Cyclooxygenase Isoforms
Potter, C. M. F., Lundberg, M. H., Mackenzie, L. S., Warboys, C. M., Warner, T. D., Berson, R. E., Moshkov, A. V., Gorelik, J., Weinberg, P. D., & Mitchell, J. A. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.214031 · Cited by 87
Cabassi, A., Tedeschi, S., Perlini, S., Verzicco, I., Volpi, R., Gonzi, G., & Canale, S. D. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319848105 · Cited by 89
“In 2004, rofecoxib was withdrawn from the market because of concerns over an increased risk in MI and strokes associated with a long-term (beginning after 18 months of continuous therapy in the Adenomatous Polyp PRevention On Vioxx (APPROVe) study), and a high-dose usage.(83) Other evidence indicated an earlier rise i…”
BackgroundMurray, M. T., Hraiki, A., Bebawy, M., Pazderka, C., & Rawling, T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.008 · Cited by 101
“, 2009), but their association with adverse cardiovascular risk detracts from their use (Bresalier et al., 2005).”
BackgroundFioravanti, A., Giannitti, C., Bellisai, B., Iacoponi, F., & Galeazzi, M. (2011) · International Journal of Biometeorology · doi:10.1007/s00484-011-0447-0 · Cited by 86
“…use of NSAIDs is limited by their negative side effects on the gastrointestinal tract and on cartilage metabolism (Ofman et al. 2002; Huskisson et al. 1995), while the use of coxibs is associated with an increase in cardiovascular adverse events (AEs) (Bresalier et al. 2005; Kearney et al 2006).”
BackgroundAngiogenesis in malignant glioma—A target for antitumor therapy?
Tuettenberg, J., Friedel, C., & Vajkoczy, P. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.01.004 · Cited by 91
“In some patients, the latter may interfere ith cardiovascular and cerebrovascular ischemic disease s it has been recently observed with the chronic adminisration of COX-2 inhibitors [124,125].”
BackgroundCathcart, M., Lysaght, J., & Pidgeon, G. P. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9324-x · Cited by 94
Bertagnolli, M. M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70139-0 · Cited by 86
Saudan, M., Saudan, P., Perneger, T., Riand, N., Keller, A., & Hoffmeyer, P. J. (2007) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.89b2.17747 · Cited by 86
Persell, S. D., Murff, H. J., Roumie, C. L., Spigel, D. R., Jha, A. K., & Horng, M. S. (2005) · Cited by 86
Mutter, R. W., Lü, B., Carbone, D. P., Csiki, I., Moretti, L., Johnson, D. H., Morrow, J. D., Sandler, A. B., Shyr, Y., Ye, F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0629 · Cited by 85
Cyclooxygenase 2: protein-protein interactions and posttranslational modifications
Alexanian, A., & Sorokin, A. (2017) · Physiological Genomics · doi:10.1152/physiolgenomics.00086.2017 · Cited by 90
Radical resection of invasive endometriosis with bowel or bladder involvement—Long-term results
Fleisch, M. C., Xafis, D., Bruyne, F. D., Hucke, J., Bender, H., & Dall, P. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2005.04.007 · Cited by 86
Fendrick, A. M., & Greenberg, B. P. (2009) · Osteopathic Medicine and Primary Care · doi:10.1186/1750-4732-3-1 · Cited by 100
Anaesthesia for endoscopic sinus surgery
BAKER, A. R., & BAKER, A. B. (2010) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2010.02259.x · Cited by 84
“risk of thrombotic cardiovascular complications including myocardial infarction and stroke.(89,90) The pathophysiological mechanism is thought to be due to the decreased endothelial production of prostacyclin, which encourages vasodilation and decreases the adhesion of platelets.”
BackgroundBioactive sulfoximines: Syntheses and properties of Vioxx® analogs
Park, S. J., Buschmann, H., & Bolm, C. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.029 · Cited by 84
Stolfi, C., Fina, D., Caruso, R., Caprioli, F., Sarra, M., Fantini, M. C., Rizzo, A., Pallone, F., & Monteleone, G. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.020 · Cited by 84
Ahmetaj‐Shala, B., Kirkby, N. S., Knowles, R., Al-Yamani, M., Mazi, S. I., Wang, Z., Tucker, A. T., Mackenzie, L. S., Armstrong, P. C. J., Nüsing, R. M., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.011591 · Cited by 87
Lactobacillus Salivarius REN Inhibits Rat Oral Cancer Induced by 4-Nitroquioline 1-Oxide
Zhang, M., Wang, F., Jiang, L., Liu, R., Zhang, L., Lei, X., Li, J., Jiang, J., Guo, H., Fang, B., et al. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0427 · Cited by 83
“org Cancer Prev Res; 6(7) July 2013 689”
BackgroundInfluentialBennett, J. S., Daugherty, A., Herrington, D., Greenland, P., Roberts, H., & Taubert, K. A. (2005) · Circulation · doi:10.1161/01.cir.0000160005.90598.41 · Cited by 84
Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited
Walker, C., & Biasucci, L. M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1412799 · Cited by 90
“independently adjudicated cardiovascular events in patients treated with rofecoxib (25 mg/day) and celecoxib (400 and 800 mg/day) in the APPROVe and APC trials, respectively [107,108].”
BackgroundInfluentialCyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke
Haag, M. D. M., Bos, M. J., Hofman, A., Koudstaal, P. J., Breteler, M. M. B., & Stricker, B. H. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.11.1219 · Cited by 96
Tang, J. Y., Aszterbaum, M., Athar, M., Barsanti, F., Cappola, C., Estevez, N., Hebert, J., Hwang, J., Khaimskiy, Y., Kim, A., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0200 · Cited by 83
“≥15 BCCs at baseline 24 28% (16-43) 32% (18-48) 0.”
BackgroundInfluentialIs COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial1
Luo, C., He, M., & Bohlin, L. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00150.x · Cited by 83
Mason, R. P., Walter, M. F., McNulty, H. P., Lockwood, S. F., Byun, J., Day, C. A., & Jacob, R. F. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200605001-00003 · Cited by 86
“These experimental findings could account for the cardiotoxicity associated with chronic rofecoxib use in various trials, including the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial.6,7 The APPROVe study led to the withdrawal of rofecoxib because it confirmed an unacceptable increase in cardiovascular events w…”
BackgroundResultMicrobial Flora in NSAID-Induced Intestinal Damage: A Role for Antibiotics?
Lanas, Á., & Scarpignato, C. (2006) · Digestion · doi:10.1159/000089789 · Cited by 83
Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention
Umar, A., Steele, V. E., Menter, D. G., & Hawk, E. T. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.010 · Cited by 87
Scott, P. A., Kingsley, G. H., & Scott, D. L. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.07.013 · Cited by 83
“Patients with previous cardiac failure were excluded from five RCTs in arthritis [27,29–32], twoRCTs in non-arthritic patients [22,25] and one case–control study [14].”
BackgroundAsghar, W., & Jamali, F. (2014) · Inflammopharmacology · doi:10.1007/s10787-014-0225-9 · Cited by 89
“Later, the results of Adenomatous Poly Prevention on Vioxx (APPROVe) trial that compared 25 mg rofecoxib with placebo reported only a twofold increase (Bresalier et al. 2005).”
BackgroundGuadagni, F., Ferroni, P., Palmirotta, R., Portarena, I., Formica, V., & Roselli, M. (2007) · PubMed · Cited by 92
Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2007) · International Journal of Biological Sciences · doi:10.7150/ijbs.3.328 · Cited by 83
“Extraordinary media coverage has been given to the two RCTs wherein increases were observed in the risk of adverse cardiovascular outcomes with long term intake of well-known selective COX-2-inhibiting agents (rofecoxib and celecoxib) [57, 58 59].”
BackgroundThe challenges for cancer chemoprevention
Penny, L. K., & WALLACE, H. M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00705d · Cited by 88
Zarraga, I. G. E., & Schwarz, E. R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.003 · Cited by 92
“One such trial was the PPROVe (Adenomatous Polyp Prevention on Vioxx) tudy (8), which now stands among landmark clinical trials.”
BackgroundInfluentialAtherosclerosis and Rheumatoid Arthritis: More Than a Simple Association
Cavagna, L., Boffini, N., Cagnotto, G., Inverardi, F., Grosso, V., & Caporali, R. F. (2012) · Mediators of Inflammation · doi:10.1155/2012/147354 · Cited by 88
“These classes of drugs have been recently linked to an increased CVD risk, first for rofecoxib [60], with subsequent reduced trend in COXIBs prescription [61], and then also for other COXIBs and NDSAIDs [62].”
BackgroundRoss, J. S. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.394 · Cited by 81
Celecoxib for the treatment of musculoskeletal arthritis
Krasselt, M., & Baerwald, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1645123 · Cited by 88
Fini, L., Piazzi, G., Ceccarelli, C., Daoud, Y., Belluzzi, A., Munarini, A., Graziani, G., Fogliano, V., Selgrad, M., Garcia, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1990 · Cited by 81
“In clinical settings, anti-COX-2 drugs, extensively tested in secondary prevention studies, are highly effective, although their long-term administration is associated with a significant increased risk of cardiovascular toxicity (3-5, 24).”
BackgroundCipollone, F., & Fazia, M. L. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200605001-00006 · Cited by 84
Clinical Pharmacokinetic and Pharmacodynamic Profile of Etoricoxib
Takemoto, J. K., Reynolds, J. K., Remsberg, C. M., Vega‐Villa, K. R., & Davies, N. M. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847110-00002 · Cited by 93
Platelets an Inflammatory Force in Transplantation
Morrell, C. N., Sun, H., Swaim, A. F., & Baldwin, W. M. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01958.x · Cited by 81
“COX-2 derived prostacyclin has been noted to affect vascular remodeling and COX-2 inhibitors have been associated with increased risk of heart attack and stroke (28,29).”
BackgroundMouse models of gastrointestinal tumors
Taketo, M. M. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00190.x · Cited by 81
Ekman, E. F., Wahba, M., & Ancona, F. D. (2006) · Arthroscopy The Journal of Arthroscopic and Related Surgery · doi:10.1016/j.arthro.2006.03.012 · Cited by 81
Hauber, B., Arden, N., Mohamed, A. F., Johnson, F. R., Peloso, P. M. J., Watson, D. J., Mavros, P., Gammaitoni, A. R., Sen, S. S., & Taylor, S. D. (2012) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2012.11.007 · Cited by 87
Masclee, G. M. C., Straatman, H., Arfè, A., Castellsagué, J., Garbe, E., Herings, R. M. C., Kollhorst, B., Lucchi, S. R., Perez‐Gutthann, S., Romio, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204746 · Cited by 89
Neuromodulation Management of Chronic Neuropathic Pain in the Central Nervous System
Yu, K., Niu, X., & He, B. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201908999 · Cited by 83
Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease
Bavry, A. A., Khaliq, A., Gong, Y., Handberg, E. M., Cooper‐DeHoff, R. M., & Pepine, C. J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.02.025 · Cited by 86
“Clinical trials and systematic reviews have shown that selective cyclooxygenase-2 inhibitors increase the hazard for myocardial infarction.(1-6) This finding likely resulted in more frequent use of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) as an alternative for chronic pain”
BackgroundRay, W. A., Chung, C. P., Stein, C., Smalley, W. E., Hall, K., Arbogast, P. G., & Griffin, M. R. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.06.058 · Cited by 86
Guidelines on the management of stable angina pectoris
Skalidis, E. I., & Vardas, P. E. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl257 · Cited by 80
Ando, T., Ooba, N., Mochizuki, M., Koide, D., Kimura, K., Lee, S. L., Setoguchi, S., & Kubota, K. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3727-0 · Cited by 79
Risk Factors for Recurrent Colorectal Polyps
Hao, Y., Wang, Y., Qi, M., He, X., Ying, Z., & Hong, J. (2019) · Gut and Liver · doi:10.5009/gnl19097 · Cited by 85
The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies
Vosooghi, M., & Amini, M. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.883377 · Cited by 79
“45% higher in colon cancer patients taking Vioxx (rofecoxib) for a period of time longer than 18 months compared with a control group taking placebo [95].”
BackgroundNonaspirin NSAIDs, Cyclooxygenase 2 Inhibitors, and the Risk for Stroke
Roumie, C. L., Mitchel, E. F., Kaltenbach, L. A., Arbogast, P. G., Gideon, P. S., & Griffin, M. R. (2008) · Stroke · doi:10.1161/strokeaha.107.508549 · Cited by 92
“Outpatient visits # (median IQR) 3 (1, 7) 7 (3, 12) 7 (3, 12) 8 (4, 14) 6 (3, 10) 6 (3, 10) 7 (3, 12) 6 (3, 11)”
Pharmacoepidemiology of non-steroidal anti-inflammatory drugs
Moore, N. D., Duong, M., Gülmez, S. E., Blin, P., & Droz‐Perroteau, C. (2018) · Therapies · doi:10.1016/j.therap.2018.11.002 · Cited by 78
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?
Howes, L. G. (2007) · PubMed Central · Cited by 80
Chan, F. K. L. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0610 · Cited by 78
Rho, Y. H., Oeser, A. M., Chung, C. P., Milne, G. L., & Stein, C. M. (2009) · Archives of Drug Information · doi:10.1111/j.1753-5174.2009.00019.x · Cited by 84
Cairns, J. A. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70732-8 · Cited by 93
Barnes, N. L. P., Wärnberg, F., Farnie, G., White, D. J., Jiang, W. G., Anderson, E. L., & Bundred, N. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603593 · Cited by 78
“This was due to an increased risk of cardiovascular events following treatment with another COX-2 inhibitor Rofecoxib (Vioxxs – now withdrawn) that was highlighted following the publication of the APPROVe trial (Bombardier et al, 2000; Bresalier et al, 2005).”
BackgroundGenetic model of selective COX2 inhibition reveals novel heterodimer signaling
Yu, Y., Fan, J., Chen, X., Wang, D., Klein–Szanto, A. J., Campbell, R. L., FitzGerald, G. A., & Funk, C. D. (2006) · Nature Medicine · doi:10.1038/nm1412 · Cited by 78
Sudbø, J., Lee, J., Lippman, S., Mork, J., Sagen, S., Flatner, N., Ristimaki, A. P., Sudbø, A., Mao, L., Zhou, X. K., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67488-0 · Cited by 78
RetractedQuesada, A. R., Medina, M. Á., & Alba, E. (2007) · BioEssays · doi:10.1002/bies.20655 · Cited by 82
GI Risk and Risk Factors of NSAIDs
Laine, L. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200605001-00011 · Cited by 77
Gout in Solid Organ Transplantation
Stamp, L. K., SEARLE, M., O???Donnell, J., & Chapman, P. T. (2005) · Drugs · doi:10.2165/00003495-200565180-00004 · Cited by 77
Sim, R., Cheong, D. M. O., Wong, K. S., Lee, B. M. K., & Liew, Q. Y. (2006) · Colorectal Disease · doi:10.1111/j.1463-1318.2006.00998.x · Cited by 77
Managing pain in inflammatory bowel disease.
Docherty, M. J., Jones, R. C. W., & Wallace, M. S. (2011) · Europe PMC (PubMed Central) · Cited by 97
Ishikawa, H., Mutoh, M., Sato, Y., Doyama, H., Tajika, M., Tanaka, S., Horimatsu, T., Takeuchi, Y., Kashida, H., Tashiro, J., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00018-2 · Cited by 77
Cathcart, M. C., Reynolds, J. V., O'Byrne, K. J., & Pidgeon, G. P. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.01.006 · Cited by 80
“In addition to these observations, chronic administration of selective COX-2 inhibitors at high concentrations has been associated with an increased risk of cardiovascular events, such as thrombosis, stroke, and myocardial infarction [24-26].”
BackgroundTreatment for Barrett's oesophagus
Rees, J. R. E., Lao‐Sirieix, P., Wong, A., & Fitzgerald, R. C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004060.pub2 · Cited by 85
RetractedPrediction of post‐operative pain after a laparoscopic tubal ligation procedure
RUDIN, Å., WÖLNER‐HANSSEN, P., HELLBOM, M., & WERNER, M. U. (2008) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2008.01641.x · Cited by 76
“The concern about the association between coxibs and serious arterial thrombotic events (17) appeared early in our study period and led to a post-operative NSAID switch from celecoxib to ibuprofen (n 5 53).”
BackgroundFioravanti, A., Tenti, S., Giannitti, C., Fortunati, N. A., & Galeazzi, M. (2013) · International Journal of Biometeorology · doi:10.1007/s00484-012-0627-6 · Cited by 76
Cyclo-Oxygenase-2 and its Inhibition in Cancer: Is There a Role?
Liao, Z. X., Mason, K. A., & Milas, L. (2007) · Drugs · doi:10.2165/00003495-200767060-00001 · Cited by 82
Wan, J., Gong, X., Jiang, R., Zhang, Z., & Zhang, L. (2013) · Phytotherapy Research · doi:10.1002/ptr.4838 · Cited by 75
“However, NSAIDs have been clinically associated with gastrointestinal side effects and cardiovascular risks (Bresalier et al., 2005; Chan and Graham, 2004).”
BackgroundData Monitoring Committees — Expect the Unexpected
DeMets, D. L., & Ellenberg, S. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510066 · Cited by 72
Liu, J., Chang, B., Li, Q., Xu, L., Liu, X., Wang, G., Wang, Z., & Wang, L. (2019) · Advanced Science · doi:10.1002/advs.201801987 · Cited by 75
Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-237 · Cited by 84
“Enthusiasm for the use of selective COX-2 blocking agents in the chemoprevention of colon cancer and other malignancies has been tempered by reports of adverse effects on the cardiovascular system leading to the recall of the popular anti-arthritic compound, rofecoxib (Vioxx) [23-25], and subsequently, the cardiovascu…”
BackgroundVidal, C., Gómez‐Hernández, A., Sánchez-Galán, E., González, A., Ortega, L. M., Gómez-Gerique, J. A., Tuñón, J., & Egido, J. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110361 · Cited by 78
“…the safety of these drugs because not only a reduction but also a lack of effect or even an increase in the incidence of cardiovascular events was observed (Bombardier et al., 2000; Silverstein et al., 2000; Altman et al., 2002; Chenevard et al., 2003; Bresalier et al., 2005; Solomon et al., 2005).”
BackgroundInfluential15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Gastric Cancer
Thiel, A., Ganesan, A., Mrena, J., Junnila, S., Nykänen, A. I., Hemmes, A., Tai, H., Monni, O. M., Kokkola, A., Haglund, C. H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2518 · Cited by 75
Update on Cyclooxygenase-2 Inhibitors
Harris, R. C., & Breyer, M. D. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00890805 · Cited by 75
“Reprinted with permission from reference (146).”
Off-Label Promotion, On-Target Sales
Fugh‐Berman, A., & Melnick, D. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050210 · Cited by 74
Chang, R. W., Tompkins, D. M., & Cohn, S. M. (2020) · The American Surgeon · doi:10.1177/0003134820952834 · Cited by 74
“This was demonstrated in a randomized controlled trial evaluating rofecoxib use, leading to its FDA approval being withdrawn and subsequent removal from the market.(44,45) In a metaanalysis of 280 trials of NSAIDs versus placebo, coxibs and diclofenac had a significant increase in major vascular events than placebo.”
MethodGlasser, S. P., Salas, M., & Delzell, E. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007304776 · Cited by 89
Kamei, D., Murakami, M., Sasaki, Y., Nakatani, Y., Majima, M., Ishikawa, Y., Ishii, T., Uematsu, S., Akira, S., Hara, S., et al. (2009) · Biochemical Journal · doi:10.1042/bj20090045 · Cited by 74
Lee, S., Park, H. ‐., Ryu, W., Lee, J., Bae, H., Han, M., Lee, Y. ‐., Kwon, H., Kim, C. K., Park, E. ‐., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12140 · Cited by 73
“Although rofecoxib was withdrawn from the market [11], according to two separate systematic analyses [12,13], celecoxib does not increase the risk of cardiovascular events.”
BackgroundLeclerc, P., Idborg, H., Spahiu, L., Larsson, C., Nekhotiaeva, N., Wannberg, J., Stenberg, P., Korotkova, M., & Jakobsson, P. (2013) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2013.09.001 · Cited by 73
Cyclooxygenase-2 Inhibitors: A Painful Lesson
Sanghi, S., MacLaughlin, E., Jewell, C., Chaffer, S., Naus, P., Watson, L., & Dostal, D. (2006) · Cardiovascular & Hematological Disorders-Drug Targets · doi:10.2174/187152906777441803 · Cited by 73
“The cardiovascular risk was detected only after a much longer time of drug exposure than previous trials [158].”
ResultChen, L., & Ashcroft, D. M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1409 · Cited by 73
Dunn, W. B., Goodacre, R., Neyses, L., & Mamas, M. A. (2011) · Bioanalysis · doi:10.4155/bio.11.223 · Cited by 80
Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs
Chaiamnuay, S., Allison, J. J., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050519 · Cited by 88
Coruzzi, G., Venturi, N., & Spaggiari, S. (2007) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · Cited by 73
Mitchell, J. A., Lucas-Domínguez, R., Vojnovic, I., Hasan, K., Pepper, J., & Warner, T. D. (2006) · The FASEB Journal · doi:10.1096/fj.06-6615com · Cited by 82
Barker, J. C., DiBartola, K. K., Wee, C. E., Andonian, N. T., Abdel‐Rasoul, M., Lowery, D. S., & Janis, J. E. (2018) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000004804 · Cited by 72
kConFab Investigators, Kehm, R. D., Hopper, J. L., John, E. M., Phillips, K., MacInnis, R. J., Dite, G. S., Milne, R. L., Liao, Y., Zeinomar, N., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1135-y · Cited by 72
Combe, B. G., Swergold, G. D., McLay, J., McCarthy, T., Zerbini, C. A. F., Emery, P., Connors, L., Kaur, A., Curtis, S., Laine, L., et al. (2009) · Rheumatology · doi:10.1093/rheumatology/kep005 · Cited by 72
Schönthal, A. H. (2006) · Neurosurgical FOCUS · doi:10.3171/foc.2006.20.4.14 · Cited by 81
Ballerini, P., Contursi, A., Bruno, A., Mucci, M., Tacconelli, S., & Patrignani, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838079 · Cited by 75
“Thus, coxibs’ inhibition of COX-2-dependent PGE2 reduces the risk of sporadic colorectal adenoma recurrence (Bresalier et al., 2005; Bertagnolli et al., 2006).”
BackgroundDrug Discovery for Duchenne Muscular Dystrophy via Utrophin Promoter Activation Screening
Moorwood, C., Lozynska, O., Suri, N., Napper, A. D., Diamond, S. L., & Khurana, T. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026169 · Cited by 77
“There is some evidence that the use of selective COX-2 inhibitors may increase the risk of adverse cardiovascular events, especially in patients who already have an increased risk [53,54,55].”
Background
Metadata
- Authors
- Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Mount Sinai Hospital (CA)
- University of Birmingham (GB)
- Tufts Medical Center (US)
- Dartmouth College (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1092-1102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158131645
- Cited by
- 2,519
- References
- 34
- Citations by year
- 2026: 32 · 2025: 25 · 2024: 17 · 2023: 50 · 2022: 48 · 2021: 37 · 2020: 52 · 2019: 56 · 2018: 63 · 2017: 67 · 2016: 85 · 2015: 107 · 2014: 110 · 2013: 117 · 2012: 120
- FWCI
- 219.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- rofecoxib, cardiovascular adverse events, thrombotic complications, COX-2 inhibitors, colorectal adenoma, colorectal cancer chemoprevention, myocardial infarction, cerebral ischemic events, congestive heart failure, pulmonary edema, cardiovascular mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Lactones, Male, Middle Aged, Risk, Sulfones, Thrombosis, Colorectal Neoplasms, Incidence, Proportional Hazards Models, Single-Blind Method, Cyclooxygenase Inhibitors, Adenomatous Polyps, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.